NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Zymeworks Inc (NYSE: ZYME)

 
ZYME Technical Analysis
5
As on 21st Nov 2024 ZYME STOCK Price closed @ 13.68 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 8.79 & Strong Buy for SHORT-TERM with Stoploss of 7.89 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ZYMESTOCK Price

Open 14.80 Change Price %
High 14.99 1 Day -0.87 -5.98
Low 13.40 1 Week -3.72 -21.38
Close 13.68 1 Month 0.95 7.46
Volume 713381 1 Year 5.16 60.56
52 Week High 17.40 | 52 Week Low 6.18
 
NYSE USA Most Active Stocks
FSR 0.02 0.00%
DDR 15.44 -4.46%
TWTR 53.70 0.66%
SWN 7.11 -0.56%
BACA-U 302.00 0.67%
SNOW 171.35 31.56%
NIO 4.70 1.08%
RPAI 13.15 -3.17%
LTHM 16.51 -8.53%
F 10.80 0.65%
 
NYSE USA Top Gainers Stocks
CND-WT 0.05 400.00%
WEI 0.44 51.72%
QFTA 10.26 51.33%
MOTV 18.70 50.20%
CORR 0.03 50.00%
WE 0.50 42.86%
WE 0.50 42.86%
DMS 0.45 36.36%
USDP 0.04 33.33%
BFLY-WS 0.04 33.33%
 
NYSE USA Top Losers Stocks
QFTA-WS 0.46 -95.33%
TWND-WS 0.48 -95.12%
CHAA-WS 0.53 -94.56%
PMVC-WS 0.58 -94.10%
PIAI-WS 0.58 -94.09%
PCPC-WS 1.50 -93.83%
FTEV-WS 0.60 -93.81%
PDOT-WS 0.62 -93.65%
PSTH-WS 1.25 -93.65%
CLAA-WS 0.75 -92.26%
 
 
ZYME
Daily Charts
ZYME
Intraday Charts
Whats New @
Bazaartrend
ZYME
Free Analysis
 
ZYME Important Levels Intraday
RESISTANCE16.74
RESISTANCE15.76
RESISTANCE15.15
RESISTANCE14.55
SUPPORT12.81
SUPPORT12.21
SUPPORT11.60
SUPPORT10.62
 
ZYME Forecast November 2024
4th UP Forecast17.51
3rd UP Forecast16.28
2nd UP Forecast15.52
1st UP Forecast14.76
1st DOWN Forecast12.6
2nd DOWN Forecast11.84
3rd DOWN Forecast11.08
4th DOWN Forecast9.85
 
ZYME Weekly Forecast
4th UP Forecast15.95
3rd UP Forecast15.22
2nd UP Forecast14.77
1st UP Forecast14.32
1st DOWN Forecast13.04
2nd DOWN Forecast12.59
3rd DOWN Forecast12.14
4th DOWN Forecast11.41
 
ZYME Forecast2024
4th UP Forecast36.21
3rd UP Forecast28.98
2nd UP Forecast24.52
1st UP Forecast20.05
1st DOWN Forecast7.31
2nd DOWN Forecast2.84
3rd DOWN Forecast-1.62
4th DOWN Forecast-8.85
 
 
ZYME Other Details
Segment EQ
Market Capital 1054913664.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
ZYME Address
ZYME
 
ZYME Latest News
 
Your Comments and Response on Zymeworks Inc
 
ZYME Business Profile
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. Address: 1385 West 8th Avenue, Vancouver, BC, Canada, V6H 3V9
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service